Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7270654
Reference Type
Journal Article
Title
A case of entecavir-induced Fanconi syndrome
Author(s)
Fujii, T; Kawasoe, K; Ohta, A; Nitta, K
Year
2019
Volume
8
Issue
4
Page Numbers
256-260
Language
English
DOI
10.1007/s13730-019-00404-5
URL
https://search.proquest.com/scholarly-journals/case-entecavir-induced-fanconi-syndrome/docview/2234483122/se-2?accountid=171501
Exit
Abstract
Acquired Fanconi syndrome has been associated with the long-term ingestion of several nucleoside analogs used to treat chronic hepatitis B virus infection. However, the nucleoside analog entecavir has not been found to cause nephrotoxicity. We report a case of entecavir-induced Fanconi syndrome. Our patient was a 73-year-old man admitted to our hospital because of renal dysfunction. He also presented with hyperaminoaciduria, renal diabetes, phosphaturia, hypophosphatemia, hypokalemia, hypouricemia, and hyperchloremic metabolic acidosis, supporting a diagnosis of Fanconi syndrome. In this case, the cause of Fanconi syndrome was most likely entecavir, which had been administered as needed depending on his renal function for 5Â years. After drug discontinuation and replacement with tenofovir alafenamide fumarate therapy once a week, the patient's kidney function recovered and electrolyte anomalies partially improved. We highlight the fact that entecavir may induce severe renal dysfunction, which can cause the development of Fanconi syndrome; therefore, close monitoring of proximal tubular function is recommended during entecavir therapy.
Keywords
Antiviral Agents; 0; Nucleosides; entecavir; 5968Y6H45M; Guanine; 5Z93L87A1R; GS-7340; EL9943AG5J; Adenine; JAC85A2161; Index Medicus; Chronic hepatitis B; Entecavir; Nucleotide analog; Fanconi syndrome; Adenine -- analogs & derivatives; Hypokalemia -- etiology; Antiviral Agents -- therapeutic use; Acidosis -- etiology; Adenine -- therapeutic use; Humans; Hypophosphatemia -- etiology; Male; Treatment Outcome; Aged; Withholding Treatment; Guanine -- analogs & derivatives; Fanconi Syndrome -- blood; Hepatitis B, Chronic -- complications; Guanine -- adverse effects; Acute Kidney Injury -- complications; Acute Kidney Injury -- chemically induced; Acute Kidney Injury -- blood; Fanconi Syndrome -- drug therapy; Nucleosides -- adverse effects; Fanconi Syndrome -- chemically induced; Nucleosides -- toxicity; Acute Kidney Injury -- pathology; Guanine -- toxicity; Hepatitis B, Chronic -- drug therapy; Fanconi Syndrome -- urine
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity